Disclosures
KIDNEY DISEASES
M.A. Cadnapaphornchai reports consultancy agreements with Otsuka Pharmaceutical, honoraria from Otsuka, and an advisory or leadership role for Otsuka Tolvaptan pediatric steering committee. A. Dandurand reports employment with Cerevel Therapeutics and was an employee of Otsuka at the time of the study. A. Dandurand's spouse reports employment with Cerberus Sentinel. L.A. Greenbaum reports consultancy agreements with Advicenne, Alexion, Arrowhead Pharmaceuticals, Aurinia, Cara Therapeutics, Handok, Natera, Novartis, Otsuka, and Roche; research funding from AbbVie, Advicenne, Alexion, Apellis, Aurinia, Reata Pharmaceuticals, Roche, and Vertex; honoraria from Alexion and Otsuka; advisory or leadership role for Alexion; and DSMB payments for Akebia, Alnylam, Reata, Relypsa, Travere, and UCSD. L.M. Guay-Woodford serves a consultant for and receives honoraria from Natera, Inc. and Otsuka Pharmaceutical. M. Litwin reports consultancy agreements with Alnylam, Bayer, Otsuka, and Travere; honoraria from Alnylam, Bayer, Otsuka, and Travere; and advisory or leadership roles for Bayer and Otsuka. D. Mekahli reports consultancy for Otsuka Pharmaceuticals and Reata as a representative of the University Hospital of Leuven and the KU Leuven University; educational grants from Otsuka Pharmaceuticals and Galapagos paid to the University Hospital of Leuven—all outside the submitted work; serves on an advisory board of Galapagos, Otsuka Pharmaceuticals, Reata, and Sanofi Genzyme as a representative of the University Hospital of Leuven and KU Leuven; is a member of the European Reference Network for Rare Kidney Diseases (ERKNet); and is supported by the clinical research fund of UZ Leuven (Belgium) and the Research Foundation Flanders (FWO; G0C8920N; 1804123N). F. Schaefer reports consultancy agreements with Akebia, Alexion, Alnylam, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, GSK, Otsuka, Purespring, Relypsa, and Roche; research funding from Fresenius Medical Care; honoraria from Amgen, Kyowa Kirin, Otsuka, and Roche; textbook royalties from Springer; Scientific Advisory Board activities for Alexion and Otsuka; and is a member of ERKNet. T. Seeman reports consultancy agreements with Otsuka Pharmaceutical. L. Shi, S.E. Shoaf, and K. Sikes are employees of Otsuka Pharmaceutical.